Disease Domain | Count |
---|---|
Neoplasms | 4 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Monoclonal antibody | 1 |
Target |
Mechanism p53 Y220C modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism p53 Y220C inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism p53 Y220C modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Compound C8-1b(Sichuan University of Science & Engineering) ( p53 Y220C ) | Neoplasms More | Preclinical |
Compound C8-2b(Sichuan University of Science & Engineering) ( p53 Y220C ) | Neoplasms More | Preclinical |
Compound C8-1a(Sichuan University of Science & Engineering) ( p53 Y220C ) | Neoplasms More | Preclinical |
CN118063597 ( MPEG1 )Patent Mining | Virus Diseases More | Discovery |
CN119930579 ( CPT1A x PPARα )Patent Mining | Digestive System Disorders More | Discovery |